Bod Australia and the University of Technology Sydney (UTS) believe they might have found the secret to anti-ageing.

Bod (ASX:BDA), maker of skincare products with a focus on medicinal cannabis, has published the results of a three-year study conducted with UTS that has found a novel family of proteins in human cells that provide antioxidant protective effects when applied to skin cells.

  • Scroll down for more ASX health news today>>>

It says this may lead to new topical application products that can help guard against the skin ageing process, and the two are exploring whether the proteins can be used as a delivery method for cannabidiol and hemp extracts.

The news certainly got shareholders excited, with BOD shares jumping to 63c, a 21 per cent increase on yesterday’s close of 52c.

“The results of this three year collaboration provide us a fantastic commercial opportunity in both the anti-ageing and cannabis markets which are both rapidly growing and ever changing,” Jo Patterson, Bod CEO, said.

“The company is in the position to develop a suite of products that utilise these novel proteins in combination with specific CBD extracts and other cannabis compounds, allowing for increased optionality over its broader product suite. This will position Bod with an IP protected and patentable product suite building greater value for the total business.”

The proteins were found to be key players in protecting cells and helping to increase both their tolerance and recovery to ultraviolet light, along with other sources of oxidative damage when over-expressed in mammalian cells. Further experiments showed increased levels of antioxidant activity, cellular growth and metabolism.

Professor Stella Valenzuela described the scientific discoveries as “extremely exciting and promising”.

“They offer a number of new opportunities for translation of our research into products for use in the beauty and health care area,” she said.

Bod and UTS will now look in to how to incorporate the proteins, and potentially plant extracts, into skin creams, with Bod saying it hopes to update shareholders soon on the commercialisation process.


In other ASX health news this morning…

The ASX’s best health company flies to new highs. CSL (ASX:CSL) hit record highs this morning, jumping to $235.66 a share thanks to a 17 per cent increase in profit (in excess of $1.9 billion). That pushed the company’s market cap to over 12 figures, putting it above Westpac (ASX:WBC) and behind only the Commonwealth Bank (ASX:CBA) and BHP (ASX:BHP) in terms of market cap on the ASX.
Nuheara (ASX:NUH) shares jump 22pc on autism news. Australia’s National Disability Insurance Scheme (NDIS) has added Nuheara as a registered provider, which pushed shares up to 3.9c. Nuheara’s product range, which can be purchased using NDIS approved funding, will be available under the hearing equipment category with the intention to support people with autism.
Heart imaging paying off for Osprey Medical (ASX:OSP). The company posted a 54 per cent increase in revenue, to $2.7 million, for the first half of 2019. That was largely thanks to growth in sales of its DyeVert system, designed to make heart imaging procedures safer for patients with poor kidney function by using safer dye.